Literature DB >> 18076647

Altered spatial distribution of PV-cortical cells and dysmorphic neurons in the somatosensory cortex of BCNU-treated rat model of cortical dysplasia.

Ramona Frida Moroni1, Francesca Inverardi, Maria Cristina Regondi, Ferruccio Panzica, Roberto Spreafico, Carolina Frassoni.   

Abstract

PURPOSE: Cortical dysplasia (CD) represents a wide range of histopathological abnormalities of the cortical mantle that are frequently associated with drug-resistant epilepsy. Recently, carmustine (1-3-bis-chloroethyl-nitrosurea [BCNU]), given to pregnant rats on embryonic day (E) 15, has been used to develop an experimental model mimicking human CD. The aim of this study was to characterize cytological and histological alterations in this model, and compare the results with those observed in human CD.
METHODS: Pregnant rats were given intraperitoneal injections of BCNU on E15. Sections of cerebral cortex from adult BCNU-treated rats were cytoarchitecturally and immunohistochemically analyzed using anti-SMI311, anticalbindin (CB), and antiparvalbumin (PV) antibodies. The density of the PV-immunoreactive (PV-ir) interneurons was quantitatively assessed by means of a two-dimensional cell-counting technique, and the spatial distribution of PV-ir neurons was evaluated by using the Voronoi tessellation.
RESULTS: The morphological features included reduced cortical size, laminar disorganization, and heterotopic clusters of neurons. We also identified large, disoriented SMI311-positive pyramidal neurons, and dysmorphic neurons intensely immunostained for neurofilaments, similar to those observed in human dysplastic cortex. An altered distribution of PV-immunoreactive cortical interneurons was also present.
CONCLUSIONS: Although some of the cytoarchitectural abnormalities found in BCNU-exposed cortex are similar to those found in other CD models, we identified new alterations that recall the neuropathological description of type IIA (Taylor's type) CD. BCNU-treated rat could therefore be a useful additional model for investigating the pathogenic mechanisms involved in this CD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18076647     DOI: 10.1111/j.1528-1167.2007.01440.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

1.  Targeted disruption of layer 4 during development increases GABAA receptor neurotransmission in the neocortex.

Authors:  J Abbah; Maria F M Braga; S L Juliano
Journal:  J Neurophysiol       Date:  2013-10-23       Impact factor: 2.714

2.  Axon Initial Segment Structural Plasticity is Involved in Seizure Susceptibility in a Rat Model of Cortical Dysplasia.

Authors:  Zong-Wei Yue; Ye-Lan Wang; Bo Xiao; Li Feng
Journal:  Neurochem Res       Date:  2018-02-21       Impact factor: 3.996

3.  Altered migratory behavior of interneurons in a model of cortical dysplasia: the influence of elevated GABAA activity.

Authors:  J Abbah; S L Juliano
Journal:  Cereb Cortex       Date:  2013-04-09       Impact factor: 5.357

4.  N,N'-Bis(2-chloroethyl)-N-nitrosourea (BCNU)-induced Apoptosis of Neural Progenitor Cells in the Developing Fetal Rat Brain.

Authors:  Tsuyoshi Yamaguchi; Hiroyuki Kanemitsu; Satoshi Yamamoto; Masahiko Komatsu; Hiroyuki Uemura; Kazutoshi Tamura; Tomoyuki Shirai
Journal:  J Toxicol Pathol       Date:  2010-04-05       Impact factor: 1.628

5.  Structural changes in the neocortex as correlates of variations in EEG spectra and seizure susceptibility in rat brains with different degrees of dysplasia.

Authors:  Zuzanna Setkowicz; Kinga Gzielo; Michal Kielbinski; Krzysztof Janeczko
Journal:  J Comp Neurol       Date:  2021-12-22       Impact factor: 3.028

6.  Morphological and Calcium Signaling Alterations of Neuroglial Cells in Cerebellar Cortical Dysplasia Induced by Carmustine.

Authors:  Cynthia Alejandra Rodríguez-Arzate; Marianne Lizeth Martínez-Mendoza; Israel Rocha-Mendoza; Yryx Luna-Palacios; Jacob Licea-Rodríguez; Ataúlfo Martínez-Torres
Journal:  Cells       Date:  2021-06-23       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.